{"id":4628,"date":"2018-04-10T08:25:41","date_gmt":"2018-04-10T08:25:41","guid":{"rendered":"http:\/\/imas12.es\/en\/?p=4628"},"modified":"2018-04-10T08:25:41","modified_gmt":"2018-04-10T08:25:41","slug":"dos-investigadores-del-instituto-i12-han-coordinado-un-documento-de-consenso-para-el-manejo-de-las-infecciones-relacionadas-con-el-uso-de-nuevos-farmacos-biologicos","status":"publish","type":"post","link":"https:\/\/imas12.es\/en\/dos-investigadores-del-instituto-i12-han-coordinado-un-documento-de-consenso-para-el-manejo-de-las-infecciones-relacionadas-con-el-uso-de-nuevos-farmacos-biologicos\/","title":{"rendered":"Dos investigadores del Instituto i+12 han coordinado un documento de consenso para el manejo de las infecciones relacionadas con el uso de nuevos f\u00e1rmacos biol\u00f3gicos"},"content":{"rendered":"<p>El Prof. Jos\u00e9 Mar\u00eda Aguado, Catedr\u00e1tico de Medicina y Jefe de la Unidad de Enfermedades Infecciosas del Hospital Universitario 12 de Octubre, ha coordinado con el Dr. Mario Fern\u00e1ndez Ruiz, investigador de dicha Unidad, un importante documento de consenso europeo titulado &#8220;<em>Consensus Document on the safety of targeted and biological therapies<\/em>&#8221; que servir\u00e1 como gu\u00eda de la Sociedad Europea de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (ESCMID) para el manejo de las infecciones relacionadas con el uso de nuevos f\u00e1rmacos biol\u00f3gicos. Un tema de una enorme relevancia en la actualidad en el \u00e1rea del c\u00e1ncer y de las enfermedades inflamatorias, en el que el Hospital tiene gran experiencia. El documento est\u00e1 constituido por 8 manuscritos que ya han sido publicados por separado y que ser\u00e1n editados pr\u00f3ximamente como un numero monogr\u00e1fico\u00a0especial en la revista <em>Clinical Microbiology Infection<\/em>,\u00a0\u00f3rgano oficial de ESCMID.<\/p>\n<p>Acceso a los manuscritos:<\/p>\n<ol>\n<li><a href=\"http:\/\/imas12.es\/wp-content\/uploads\/2018\/Varios\/Noticia_CMI\/Fernandez_Ruiz%20ESGICH_Biologicals_Introduction.pdf\" target=\"_blank\" rel=\"noopener\">Introduction<\/a><\/li>\n<li><a href=\"http:\/\/imas12.es\/wp-content\/uploads\/2018\/Varios\/Noticia_CMI\/Aguilar.Onco.ESGICH%20Consensus%20in%20targeted%20therapies-%20cell%20surface%20receptors.pdf\" target=\"_blank\" rel=\"noopener\">Cell surface receptors and associated signaling pathways<\/a><\/li>\n<li><a href=\"http:\/\/imas12.es\/wp-content\/uploads\/2018\/Varios\/Noticia_CMI\/Baddley.anti_TNF.ESGICH.pdf\" target=\"_blank\" rel=\"noopener\">Soluble immune effector molecules [I]: anti-tumour necrosis factor-a agents<\/a><\/li>\n<li><a href=\"http:\/\/imas12.es\/wp-content\/uploads\/2018\/Varios\/Noticia_CMI\/Whintrop.Agents%20targeting%20interleukins%20immunoglobulins%20complement.pdf\" target=\"_blank\" rel=\"noopener\">Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors<\/a><\/li>\n<li><a href=\"http:\/\/imas12.es\/wp-content\/uploads\/2018\/Varios\/Noticia_CMI\/Mikulska(1).CMI.pdf\" target=\"_blank\" rel=\"noopener\">Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52<\/a><\/li>\n<li><a href=\"http:\/\/imas12.es\/wp-content\/uploads\/2018\/Varios\/Noticia_CMI\/Drgona_etal.%20ESGICH%20Consensus%20Document%20on%20the%20safety%20of%20targeted%20and%20biological%20the.pdf\" target=\"_blank\" rel=\"noopener\">Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4<\/a><\/li>\n<li><a href=\"http:\/\/imas12.es\/wp-content\/uploads\/2018\/Varios\/Noticia_CMI\/Gil-Redelman.ESGICH_Immune%20checkpoint%20inhibitors%20cell%20adhesion%20inhibitors%20sphingosine-1-phosphate.pdf\" target=\"_blank\" rel=\"noopener\">Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors<\/a><\/li>\n<li><a href=\"http:\/\/imas12.es\/wp-content\/uploads\/2018\/Varios\/Noticia_CMI\/Reinwald.%20tyrosine%20kinase%20and%20mTOR.ESGICH.pdf\" target=\"_blank\" rel=\"noopener\">Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>El Prof. Jos\u00e9 Mar\u00eda Aguado, Catedr\u00e1tico de Medicina y Jefe de la Unidad de Enfermedades Infecciosas del Hospital Universitario 12 de Octubre, ha coordinado con el Dr. Mario Fern\u00e1ndez Ruiz, investigador de dicha Unidad, un importante documento de consenso europeo&#8230;<\/p>\n","protected":false},"author":8,"featured_media":4629,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4628","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categoria"],"_links":{"self":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/posts\/4628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/comments?post=4628"}],"version-history":[{"count":2,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/posts\/4628\/revisions"}],"predecessor-version":[{"id":4631,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/posts\/4628\/revisions\/4631"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/media\/4629"}],"wp:attachment":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/media?parent=4628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/categories?post=4628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/tags?post=4628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}